Predrag Sikirics group (School of Medicine, University of Zagreb, 1991 ) Most common experimental dose in animal studies: 10 g/kg intraperitoneally or per os, daily Standard targeted pathways: VEGFR2 angiogenesis, NO synthase , 5-HT2A serotonin receptor, dopamine D2 receptor Clinical program in Croatia halted at Phase 2 (Crohns disease) WADA Prohibited List: added in 2022 to category S0 (Non-Approved Substances) Reference sources (PubMed) Sikiric P
it offers pathway-level context for a conversation with your provider
The FDA states that it will not make a final determination until it has considered the committees input and completed its remaining reviews
These are natural substances, such as blood components, cells, and growth factors, that can speed up the healing process of damaged tendons, ligaments, muscles, and bones